Physician profile
Amy J Albert
NPI 1952303711
$3,331.25
in general payments reported to CMS, 2019-2025
25 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $145 · 2021: $398 · 2022: $204 · 2023: $806 · 2024: $313 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,366.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,358.73 | 2021-2025 | Xeomin |
| Corium, LLC | $304.95 | 2022-2024 | Azstarys |
| Sun Pharmaceutical Industries INC. | $246.74 | 2025 | |
| Supernus Pharmaceuticals, INC. | $239.19 | 2021-2022 | |
| Abbvie INC. | $206.72 | 2023-2025 | |
| Neos Therapeutics, LP | $160.28 | 2019-2023 | Adzenys Xr-Odt |
| Allergan, INC. | $128.25 | 2019 | |
| Alk-Abello, INC | $109.27 | 2023-2024 | Odactra, Ragwitek, Grastek |
| Amgen INC. | $87.66 | 2025 | Otezla |
| Ironshore Pharmaceuticals INC. | $82.25 | 2019-2024 | |
| Adlon Therapeutics L.P. | $53.08 | 2020-2021 | |
| Tris Pharma INC | $52.28 | 2020-2022 | |
| Verrica Pharmaceuticals INC. | $39.06 | 2024 | Ycanth |
| Takeda Pharmaceuticals U.S.A., INC. | $33.22 | 2021 | |
| Sobi, INC | $28.52 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.16 | 2019-2024 | Bexsero |
| Novartis Pharmaceuticals Corporation | $27.29 | 2025 | |
| Rhodes Pharmaceuticals L.P. | $24.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.99 | 2023 | Spevigo |
| Incyte Corporation | $18.03 | 2025 | Opzelura |
| Vertical Pharmaceuticals, LLC | $17.94 | 2019 | |
| Janssen Biotech, INC. | $16.93 | 2024 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $15.96 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.70 | 2025 | Cabtreo |
| Sanofi Pasteur INC. | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.